retatrutide phase 2 trial results Triple–Hormone-Receptor Agonist for Obesity — A | NEJM Retatrutide TRANSCEND-T2D-1 topline results are

The drug pipelines have diversified

In LEAD-2 and LEAD-5, investigators reported that SBP reductions occurred prior to substantial weight loss and may not have been fully explained by changes in body weight

Is Mounjaro safe to use alongside other weight loss treatments

An AG may be marketed by the brand name drug company or another company with the brands permission

Guideline Recommendations Guidelines and expert consensus on the clinical use of GLP-1RAs suggest that GLP-1RAs reduce cardiovascular risk in T2DM (eg, 2020 Chinese Guidelines for the Prevention and Control of Type 2 Diabetes Mellitus, 2022 Chinese Clinical Guidelines for the Prevention and Control of Type 2 Diabetes Mellitus in the Elderly, and 2023 American Diabetes Association Standards for the Medical Diagnosis and Treatment of Diabetes Mellitus)